Public Release Type:
Journal
Publication Year: 2012
Authors:
Daly AK,
Kleiner DE,
Aithal GP,
Allison ME,
Andrade RJ,
Anstee QM,
Bedossa P,
Burt AD,
Chalasani NP,
Clement J,
Clément K,
Cordell HJ,
Darlay R,
Day CP,
Kotronen A,
Leathart JB,
Pihlajamaki J,
Ratziu V,
Reeves H,
Romero-Gomez M,
Rotter J,
Stickel F,
Valenti L,
Van Gaal L,
Yki-Jarvinen H
Studies:
Nonalcoholic Steatohepatitis Clinical Research Network
Inter-patient genetic variation and environment determine severity and progression of non-alcoholic fatty liver disease (NAFLD). Most individuals with the metabolic syndrome develop steatosis, but only a minority exhibit progressive disease characterised by steatohepatitis (NASH) and fibrosis. Previous genome-wide association studies (GWAS) have provided important insights into modifier genes but most have been imaging based and so phenotype-limited to steatosis as histological assessment is required to identify features of steatohepatitis and fibrosis.